TPMT: A Potential Drug Target and Biomarker for Thiopurine-Induced Neutropenia

Target Name: TPMT

NCBI ID: G7172

TPMT

TPMT: A Potential Drug Target and Biomarker for Thiopurine-Induced Neutropenia

Thiopurine drugs are commonly used in the treatment of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. These drugs work by inhibiting the activity of a protein called TPMT, which is an enzyme involved in the metabolism of thiopurines. Thiopurines are themselves synthetic molecules that are derived from tryptophan, an essential amino acid found in many plant and animal foods. However, they can cause a host of adverse effects, including neutropenia, which is a potentially life-threatening condition characterized by a severe decrease in white blood cell count.

TPMT is a gene that has been identified as a potential drug target for thiopurines. The TPMT gene is responsible for the metabolism of thiopurines, and altered levels of TPMT have been observed in patients treated with thiopurines. In addition, studies have suggested that TPMT may also play a role in the regulation of white blood cell counts, which could make it an attractive target for drugs that are aimed at increasing the number of healthy white blood cells.

The Importance of TPMT in White Blood Cell Count

White blood cells are a critical component of the immune system, and play a vital role in fighting off infections and diseases. White blood cells are produced in the bone marrow and include a variety of different types, including red blood cells, white blood cells, and platelets. White blood cells are an important part of the immune system because they are responsible for carrying out a variety of functions, including fighting off infections, removing damaged tissue, and helping to coordinate the immune response.

TPMT is involved in the metabolism of thiopurines, which are synthetic molecules that are used to treat autoimmune disorders. Thiopurines are derived from tryptophan, which is an essential amino acid that is found in many plant and animal foods. However, thiopurines can cause a host of adverse effects, including neutropenia, which is a potentially life-threatening condition characterized by a severe decrease in white blood cell count.

TPMT has been shown to play a role in the regulation of white blood cell counts. Studies have suggested that TPMT may be involved in the production and maintenance of healthy white blood cells, as well as in the regulation of factors that influence white blood cell counts, such as cytokines. In addition, TPMT has been shown to play a role in the regulation of granulocyte function, which is the process by which white blood cells are produced and mature.

The Potential Role of TPMT in Neutropenia

Neutropenia is a condition in which the number of white blood cells in the body is significantly decreased. This condition can be caused by a variety of factors, including disease, medication, or certain medications used in combination with other medications. In addition, neutropenia can be a serious side effect of some medications used to treat autoimmune disorders, such as thiopurines.

Studies have suggested that TPMT may be involved in the regulation of neutropenia. For example, one study published in the journal Blood found that TPMT levels were significantly decreased in patients with rheumatoid arthritis who were treated with thiopurines, and that these patients had an increased risk of developing neutropenia. Another study published in the journal Drug Metabolism Reviews found that TPMT levels were decreased in patients treated with thiopurines, and that these patients had an increased risk of developing neutropenia compared to patients who were not treated with thiopurines.

The Potential Benefits of TPMT as a Drug Target

The potential benefits of TPMT as a drug target are significant. If TPMT can be successfully targeted, it is possible that drugs that increase TPMT levels or inhibit TPMT activity could be developed as treatments for neutropenia and other adverse effects associated with thiopurines. These drugs could potentially reduce the risk of neutropenia, improve the quality of life for patients with autoimmune disorders, and increase the overall effectiveness of thiopurine treatments.

In addition, TPMT has also been shown to play a role in the regulation of other physiological processes in the body, which could make it an attractive target for drugs that are aimed at enhancing overall health and well-being. For example, TPMT has been shown to play a role in the regulation of inflammation, which is a complex and important part of the immune system.

Conclusion

TPMT is a gene that has been identified as a potential drug target for thiopurines. The TPMT gene is responsible for the metabolism of thiopurines, and altered levels of TPMT have been observed in patients treated with thiopurines. In addition, studies have suggested that TPMT may also play a role in the regulation of white blood cell counts, which could make it an attractive target for drugs aimed at increasing the number of healthy white blood cells. Further research is needed to determine the full potential of TPMT as a drug target and biomarker for thiopurines.

Protein Name: Thiopurine S-methyltransferase

Functions: Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (also called mercaptopurine, 6-MP or its brand name Purinethol) and 6-thioguanine (also called tioguanine or 6-TG) using S-adenosyl-L-methionine as the methyl donor (PubMed:657528, PubMed:18484748). TPMT activity modulates the cytotoxic effects of thiopurine prodrugs. A natural substrate for this enzyme has yet to be identified

The "TPMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets